Obenauf Lab

Research focus

ERC Consolidator Grant · 2023

Unlocking a T cell-mediated Immune response in therapy-challenged Tumors

Immuno- and targeted therapies have revolutionized the treatment of cancer patients, and more innovative therapeutics, such as KRAS inhibitors (KRASi), are entering the clinic. However, their use as monotherapies fails to achieve durable tumor control in most patients, and the development of combination therapies remains challenging without an understanding of the complex and dynamic biology that unfolds upon therapeutic challenge in the tumor microenvironment (TME). Most of our knowledge on combination therapies is based on primary, treatment-naïve tumors, but how signaling networks of cancer cells and their interactions with immune cells evolve under therapeutic challenge over time is…

From the public funding record at EU CORDIS. Describes the funded project, not the reviews below.